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ABSTRACT
The elaboration of polarity is central to organismal development and
to the maintenance of functional epithelia. Among the controls
determining polarity are the PAR proteins, PAR6, aPKCι and PAR3,
regulating both known and unknown effectors. Here, we identify
FARP2 as a ‘RIPR’ motif-dependent partner and substrate of aPKCι
that is required for efficient polarisation and junction formation.
Binding is conferred by a FERM/FA domain–kinase domain
interaction and detachment promoted by aPKCι-dependent
phosphorylation. FARP2 is shown to promote GTP loading of
Cdc42, which is consistent with it being involved in upstream
regulation of the polarising PAR6–aPKCι complex. However, we
show that aPKCι acts to promote the localised activity of FARP2
through phosphorylation. We conclude that this aPKCι−FARP2
complex formation acts as a positive feedback control to drive
polarisation through aPKCι and other Cdc42 effectors.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
Atypical protein kinase Cs (PKC), aPKCζ and aPKCι, are serine/
threonine specific protein kinases that form a distinctive subset of
PKC proteins with characteristic regulatory inputs, outputs and
pharmacology (for a review, see Parker et al., 2014). The most
well-characterised physiological role relates to aPKCι and its
requirement for determining asymmetric/polarised cellular
behaviours (reviewed in Chen and Zhang, 2013; Suzuki and
Ohno, 2006). This was initially established in Caenorhabditis
elegans (Tabuse et al., 1998) where the aPKC orthologue, along
with other PAR proteins, have been shown to play critical roles in
cell polarisation; the same conserved modules, aPKC, PAR6 and
PAR3, were subsequently shown to operate in mammals (note in
mammals there are several PAR6 and PAR3 family proteins)
(Joberty et al., 2000).
The direct interaction of aPKCι with regulatory proteins and
substrates is a particular feature of its action. In C. elegans there is a
dynamic cycling between highly localised PAR3-containing aPKCι
complexes (inactive) and dispersed Cdc42 containing complexes
(active) (Rodriguez et al., 2017); the inactivity being determined by
interaction of the CR3 region of PAR3 with the substrate-binding
pocket of aPKCι (Soriano et al., 2016). Mutation of the aPKCι RIPR
partner interaction motif, as seen rarely but repeatedly in cancers,
leads to a failure of the mutant protein to support normal polarisation
(Linch et al., 2013). In pathophysiological states, aPKCι
hyperactivation through Ras-dependent mechanisms can also drive
a loss of polarity (Linch et al., 2014); such aPKC hyperactivation has
been reported to overcome contact inhibition through Hippo/Yap
signalling (Archibald et al., 2015). This suppression of polarity-
dependent growth inhibition is consistent with a role in tumorigenesis
as seen in an inducible lung model of Ras-dependent tumour
formation (Regala et al., 2009).
FERM, RhoGEF and pleckstrin domain-containing proteins
(FARPs) are guanine nucleotide exchange factors (GEFs) for Rho
family proteins (Kubo et al., 2002; Ni et al., 2003; Toyofuku et al.,
2005), and FARP2 is identified here as a protein partner in an aPKCι
interactome screen. FARP2 is shown to act as a GEF for the
upstream polarity regulator Cdc42 (Noda et al., 2001); however, we
demonstrate that FARP2 also acts downstream of aPKCι, where it
controls polarity. The aPKCι–FARP2 module thus comprises a
novel positive feedback control acting to regulate polarity through
its own assembly and turnover.
RESULTS AND DISCUSSION
aPKCι interacts with and phosphorylates FARP proteins
A proteomics screen for endogenously expressed proteins associating
with aPKCι in HCT116 cells revealed that FARP2 is an aPKCι
interactor (Fig. S1A). We validated the interaction of aPKCι with
FARPs by co-expression with aPKCι and immunoprecipitation
(antisera to the endogenous protein was not effective for native
aPKCι recovery). aPKCι efficiently binds to both FARP1 and FARP2
(Fig. 1A,B). Complex formation with FARP2 was corroborated
in cells employing a fluorescence resonance energy transfer–
fluorescence-lifetime imaging microscopy (FRET-FLIM)-based
approach (Fig. S1B). Co-expression with aPKCι revealed anReceived 9 August 2018; Accepted 28 February 2019
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Fig. 1. See next page for legend.
2
SHORT REPORT Journal of Cell Science (2019) 132, jcs223743. doi:10.1242/jcs.223743
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
increase in overall and PKC-mediated phosphorylation of FARP1/2,
as revealed by ProQ Diamond staining and phosphorylated serine
(pSer) PKC substrate immunostaining, respectively (Fig. 1C).
Increased phosphorylation of FARP1/2 was inhibited by a pre-
incubation with the aPKCι specific inhibitor CRT0066854 (Kjaer
et al., 2013), indicating that both FARP proteins are phosphorylated
under aPKCι control (Fig. 1C).
Through co-immunoprecipitation, we established that FARP2 is a
RIPR motif-dependent partner (Fig. 1C) (Linch et al., 2013).
Furthermore, through deletion mapping, we found that aPKCι
interacts with FARP2 via its FERM and FERM-adjacent (FA)
domains (Fig. S1C), a conserved domain pair retained in various
proteins (seeMoleirinho et al., 2013). Interaction with FARP2 could
be reproduced when using the aPKCι kinase domain alone.
Furthermore a stoichiometric complex of the GST–kinase domain
and the FARP2 FERM-FA domains could be isolated from sf9 cells,
indicating that these regions are sufficient for interaction, although
not stable to subsequent gel filtration once cleaved from the GST
fusion partner (Fig. S1D).
FARP2 but not FARP1 is required for polarity in Caco2 cells
Using ZO-1 (also known as TJP1) staining as a proxy for intact,
polarised cell–cell contacts, we found impaired establishment of
cell–cell junctions in cells depleted of FARP2 (siFARP2), but not
of FARP1 (siFAPR1) (Fig. 1D; see knockdown Fig. S1E). This
phenocopies what is seen upon Cdc42 and aPKCι depletion
(Figs S2A and S3B). Consistent with this altered behaviour after
knockdown of FARP2, aPKC was also lost from cell–cell
junctions (Fig. S2B). Furthermore, only FARP2 depletion resulted
in a loss of trans-epithelial resistance (TER), a functional marker of
intact cell–cell contacts (Fig. 1E,F). In a direct assessment of
polarity, knockdown of FARP2 also phenocopied the knockdown
of either Cdc42 or aPKCι in a Caco 3D lumen formation assay
(Durgan et al., 2011), indicative of a loss of polarised
morphogenesis (Fig. 1G,H).
FARP2 is required for efficient initiation of junction formation
To assess whether FARP2 also had a role in junctional initiation,
cells were subjected to a Ca2+ switch (Elbediwy et al., 2012).
Depletion of FARP2 prevented proper junctional establishment, as
evident through the disorder of the marker ZO-1; this was seen
prominently at 8 h post Ca2+ re-addition, phenocopying the effects
of aPKCι and Cdc42 knockdown (Fig. 2A). Following depletion of
FARP2 with a validated siRNA, we found that the TER was
significantly reduced (∼40%), which is a similar level of reduction
to what is seen upon aPKCι or Cdc42 depletion (Fig. 2B). These
effects were also observed with a second FARP2 siRNA (Fig. S3A).
To assess the penetrance of this dependence on FARP2 for
de novo junction formation, we employed A431 cells. When these
cells are serum-starved, ZO-1 is lost from cell–cell contacts and
upon addition of EGF, ZO-1 relocalises in a time-dependent
fashion as tight junctions (TJs) re-form (Van Itallie et al., 1995). We
depleted FARP2 and assessed ZO-1 localisation at time 0 and
30 min post EGF addition. We found that the normal coherent
localisation of ZO-1 became severely fragmented upon depletion
of FARP2, further validating a role for FARP2 in junction
establishment (Fig. 2C). By using individual siRNAs directed at
FARP2 in Caco-2 cells, we also observed a disruption of ZO-1
localisation (Fig. S3B) and a drop in TER, albeit to a lesser extent
than observed in the establishment assay (Fig. S3C). This indicates
that FARP2 is involved primarily in junctional establishment but
also to some extent in their maturation and/or maintenance. It is
surmised that removal of the GEF results in aberrant signalling,
disrupting cell–cell contacts.
FARP2 acts as a Cdc42-GEF in Caco2 cells
There are differences observed with respect to the G-protein
specificity of FARP proteins (see Kubo et al., 2002; Miyamoto
et al., 2003). To assess whether FARP2 acts through its GEF activity
for junction establishment we used a G-LISA activation assay.
FARP2 depletion significantly affected the levels of active Cdc42
(Fig. 3A), while having no significant effect on Rac1, Rac2 or Rac3
(Fig. S4A). We further assessed this with an anti-Cdc42-GTP
antibody (Elbediwy et al., 2012). In control cells, Cdc42-GTP
localises in part to the TJs, while on FARP2 depletion, its junctional
localisation is disrupted (Fig. 3B), suggesting that FARP2 is indeed
a GEF for Cdc42 in this model. This is consistent with the notion
that FARP2 acts to increase Cdc42-GTP levels and hence triggers
aPKCι activation acting through PAR6 (Noda et al., 2001), and that
all three proteins are required for the initiation and maintenance of
polarity (see Chen and Zhang, 2013; Suzuki and Ohno, 2006).
However, it transpires this is a more complex feedback control
pathway as indicated by the influence of aPKCι on FARP2.
aPKCι phosphorylates sites in the FARP2 FERM-FA domains
to control polarity
In silico analysis and in vitro peptide screening with recombinant
aPKCι identified two candidate phosphorylation sites in FARP2
that are also conserved in FARP1 and partially in two EPB41 family
members (Fig. S4B); both FARP2 sites, S340 and S370, are located
in the FERM-FA domain where aPKCι interacts. To test whether
these sites were phosphorylated by aPKCι in cells, we co-expressed
aPKCι with wild-type FARP2 (FARP2 WT) or FARP2 with
phosphorylation-resistant mutants (S340A/S370A mutations).
Analysis via immunoblotting with antibodies that recognise the
motifs surrounding either S340 or S370, revealed that these sites
could be targeted by aPKCι in a manner inhibited by the selective
drug CRT0066854 (Kjaer et al., 2013) (Fig. 3C). Consistent with
Fig. 1. FARP2 is a RIPR-dependent substrate of aPKCι that is responsible
for maintaining tight junctions and polarity. (A,B) FARP1 and FARP2
co-precipitate with aPKC. HCT116 cells were co-transfected with plasmids
expressing FLAG-tagged FARP1 (A) or FARP2 (B) and GFP, GFP-tagged
aPKCι or GFP-tagged aPKCι containing a RIPR to AIPA mutation (R480A/
R483A). Immunoprecipitates were analysed with the indicated antibodies.
Images are of representative blots of n=3. (C) GFP–PKCι phosphorylates
FARP1 and FARP2 in cells. HCT116 cells were co-transfected with plasmids
expressing FLAG-tagged FARP1 or FARP2, and GFP or GFP-tagged aPKCι.
Immunoprecipitates (IP) were analysed via ProQ diamond staining or with the
indicated antibodies. (D) FARP2 and not FARP1 is involved in junctional
establishment after Ca2+ switch. Caco-2 cells were subjected to siRNA
treatment (p represents the use of ON-TARGETplus SMARTpool siRNA,
Dharmacon), processed for Ca2+ switch immunofluorescence and stained for
the junctional marker ZO-1. A representative example of n=3 experiments with
six coverslips per immunofluorescence experiment is shown. (E) FARP1
depletion has no effect on junctional permeability as indicated by a Ca2+ switch
TERassay. A representative example of n=3 experiments is shown. (F) FARP2
depletion has a substantial effect on junctional permeability as indicated by a
Ca2+ switch transepithelial assay. A representative example of n=3
experiments with six samples per experiment is shown. (G) 3D lumen formation
in a CaCo2 model is disturbed upon knockdown of either FARP2, Cdc42 or
PKCι. CaCo2 cells were grown onaMatrigel-coated surface as described in the
Materials and Methods. Cysts were stained for ZO-1 (green), F-actin (red) as
indicated and Hoechst 33342 (stained according to manufacturer’s
instructions; Sigma-Aldrich) (blue). (H) Quantification of the proportion of single
lumen cysts forexperiments as inG. n≥100 cystswere counted perexperiment.
Results are mean±s.d. ns, not significant (P>0.05); ***P≤0.001; ****P≤0.0001
(unpaired t-test). siCtrl, control siRNA. Scale bars: 20 μm.
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Fig. 2. FARP2 is required for efficient initiation of junction formation. (A) Individual siRNA oligonucleotides directed at FARP2 cause severe disruption
of ZO-1 during junction establishment (see also Fig. S2). A representative example or n=3 with six samples per experiment is shown. (B) FARP2, aPKC and Cdc42
siRNA deconvolution in a Ca2+ switch assay. The TER is severely disrupted, indicative of loss of junctional integrity. A representative example of n=3 experiments
with five samples per experiment is shown. (C) De novo junction formation in EGF-stimulated A431 cells. Pooled siRNA (denoted by p, siGenome Pools)
directed at FARP2, aPKC or Cdc42 results in junctional impairment, indicated by the loss of integrity of ZO-1. A representative example or n=3 with six samples per
experiment is shown. Results in B are mean±s.d. ****P≤0.0001 (unpaired t-test). siCtrl, control siRNA. Scale bars: 20 μm.
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Fig. 3. See next page for legend.
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activation-dependent phosphorylation, the kinase domain was more
efficient than the full-length protein in supporting this
phosphorylation, whilst retaining the same pattern of specificity
for these two sites (Fig. 3C,D). The total absence of detectable
phosphorylation in the double S340A/S370A mutant demonstrates
that these two sites are the dominant aPKCι phosphorylation sites
recognised.
To establish the influence of aPKCι-mediated phosphorylation of
FARP2 on junction integrity, we knocked down FARP2 and assessed
rescue with siRNA resistant mutants. Upon FARP2 depletion, ZO-1
was perturbed as expected; this phenotype was reversed by
re-expressing a WT FARP2 siRNA resistant mutant. Expression of
FARP2 does not influence ZO-1 in a control siRNA background
(Fig. S4C). Notably, expressing siRNA-resistant forms of the non-
phosphorylatable mutants of FARP2 fails to rescue junctional
disruption, indicating that aPKCι-dependent phosphorylation of
FARP2 is essential for junctional integrity (Fig. 3E,F).
To assess whether phosphorylation of FARP2 acted to control
catalytic activity of FARP2 directly, we overexpressed FARP2WTor
the S340A/S370A double-mutant together with aPKCι and assessed
active Cdc42 levels using a PAK1-PBD pulldown assay. Both
FARP2 constructs led to an increase in Cdc42-GTP and this was not
influenced by aPKCι inhibition (Fig. S3G). We also sought to rescue
levels of active Cdc42 by expressing either siRNA resistant WT or
mutant FARP2 in the context of endogenous FARP2 knockdown in a
GLISA assay; expression of WT FARP2 rescued the levels of active
Cdc42 (Fig. 3H) and we observed an even stronger recovery of
Cdc42-GTP with the non-phosphorylatable mutant. The evidence is
compelling that, biochemically, phosphorylation by aPKCι does not
act directly on the GEF activity of FARP2. It is not clear why the
S340A/S370A FARP2 mutant might be more effective than WT
FARP2 in elevating steady-state levels of Cdc42-GTP. This might
reflect distinct localisation of this ectopically expressed mutant
(aligned with the conclusions relating to aPKCι action, see below),
perhaps changing its juxtaposition to Cdc42 GAPs.
Since ectopic expression typically compromises compartmentalisation
and there was a requirement for FARP2 phosphorylation in initiating
efficient junction formation, phenocopying aPKCι loss, we
determined whether GTP loading of Cdc42 was influenced by
endogenous aPKCι.We assessed the levels of active Cdc42 following
a Ca2+ switch and the associated effects of FARP2 or aPKCι
knockdown.At 8 hpostCa2+ re-addition,when the loss of polarisation
was evident (see above), the level of GTP-bound Cdc42 was
significantly reduced upon depletion of either FARP2 or aPKCι
(Fig. 3G). It appears that aPKCι exerts positive-feedback control on its
upstream regulatorCdc42 but, as determinedbyectopic co-expression
experiments, this is not a simple biochemical consequence of
phosphorylation of FARP2 by aPKCι. The effects on the
endogenous FARP2 compared to the lack of effect on the properties
of the ectopic FARP2 suggested that localisation was likely to be an
important factor in this pathway.
When FARP2 phosphorylation is blocked through aPKCι
inhibition, there was a stabilisation of the FARP2–aPKCι complex
(Fig. S4D). Similarly co-expression with a catalytically inactive
aPKCι led to an increased recovery of the complex (Fig. S4E).
Finally, consistent with the site mapping, stabilisation of the complex
was also seen upon mutation of the two identified target sites, the
effect being dominated by the S340 site and showing no influence
from aPKCι inhibition (Fig. S4F). This demonstrates that
phosphorylation of FARP2, which is required for its effects on
polarisation, is associated with turnover of its complex with aPKCι.
This led us to conclude that the release of FARP2 from the aPKCι
complex and its subsequent transition to or function at junctional
compartments (see Fig. 3E,F)might be critical to aPKCι action. Since
loss of FARP2 function disrupts ZO-1 localisation, we cannot
determine formally whether this is causal or consequential; however,
the weight of evidence on the requirements, the localisation of active
Cdc42 at junctions and the notable precedent of PAR3 behaviour
(Soriano et al., 2016) suggest that FARP2 is released to act at the
junctional compartment following aPKCι-mediated phosphorylation.
Monitoring the expression levels of aPKCι and the polarity marker
Par6 we find no effect upon FARP2 siRNA treatment, while the
localisation of aPKCι and the polarity marker ezrin is severely
affected (see Fig. S2B,C). This was confirmed by the use of
CRT0066854 and expression of the WT form of FARP2. This
construct fails to rescue the polarity phenotype seen upon aPKCι
inhibition as it requires the activity of aPKCι (Fig. S4H).
In conclusion, as illustrated in Fig. 4, we identify FARP2 as a novel
substrate of aPKCι and show that it is responsible for maintaining
Cdc42-GTP levels under polarising conditions in the Caco2 model.
Loss of any elements of this pathway compromises polarisation. As an
effector of Cdc42, aPKCι, acting with FARP2, therefore appears to act
as an amplifier. Active Cdc42 can activate a variety of additional
downstream targets (reviewed in Etienne-Manneville, 2004); hence,
this regulatory module confers a positive-feedback mechanism in
which a FARP2–Cdc42 complex will not only activate Par6–aPKCι
complexes, but also drive effector functions through additional Cdc42
downstream targets independently of aPKCι that are predicted to be
effective in distinct junctional compartment(s). Although the exact
molecular implications and the spatiotemporal importance of this
complex assembly in vivo haveyet to be elaborated, it is evident that this
module is required for effective junction formation and maintenance.
MATERIALS AND METHODS
Cell culture, antibodies and chemicals
For cell line authentication, cell lines were mycoplasma screened and short
tandem repeat (STR) profiled. The STR profile was cross referenced back to
Fig. 3. Molecular function of FARP2 and the effect of aPKCι-mediated
phosphorylation. (A) G-LISA assay assessing the levels of active Cdc42 in
CaCo2 cells transfected with either control siRNA (siCtrl) or siRNA targeting
FARP2; n=3. (B) FARP2 depletion impairs localisation of Cdc42-GTP and ZO1
at cell–cell junctions. A representative example of n=2 experiments with five
samples per experiment. (C) FARP2 is phosphorylated by aPKCι. FARP2 WT
or mutants were expressed in HCT116 cells with or without aPKCι and
immunoprecipitated (IP). Phosphorylation at S340 and S370 was assessed
using antibodies that recognise the sequence context of each site. The use of
aPKCι-specific inhibitor CRT0066854 (10 µM, 60 min) confirmed aPKCι-
mediated phosphorylation. Representative blots of n=2 experiments are
shown. (D) Active aPKCι phosphorylates FARP2 without requiring its
regulatory region. HCT116 cells were co-transfected with WT FARP2 or
mutants as indicated with or without aPKCι or its kinase domain (K.Dom.).
FARP2 was immunoprecipitated, and phosphorylation at S340 and S370 was
assessed as in C. Representative blots of n=2 experiments are shown.
(E,F) Mutation of the S340 and S370 phosphorylation sites in FARP2 prevents
siRNA-resistant FARP2 from rescuing the altered ZO-1 localisation phenotype
observed upon FARP2 depletion. The location of ZO-1 is indicated (left panels;
red in merge) alongside the GFP expression (right panels; green in merge). A
representative example of n=3 experiments with six samples per experiment is
shown. A quantitative analysis is shown in the histogram (F) as indicated for the
different rescue constructs. (G) Levels of active Cdc42 during a Ca2+ switch.
The effects of FARP2 or aPKCι knockdown at 8 h post Ca2+ re-addition result
in severe depletion of Cdc42-GTP. A representative example of n=3
experiments with six samples per experiment is shown. (H) Levels of active
Cdc42 are rescued by both the WT and mutant constructs. A representative
example of n=2 experiments with eight samples per experiment is shown.
Results are mean±s.d. *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001
(unpaired t-test). Scale bars: 20 μm.
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any available published profile for the cell line in question. If there was no
published profile available, it was checked against the Cell Services STP
database of the Francis Crick Institute, London, UK. HCT116 and Caco-2
cells were cultured as previously described (Linch et al., 2013; Soriano
et al., 2016). A431 cell experiments were performed as previously described
(Elbediwy et al., 2012; Van Itallie et al., 1995). Briefly, A431 cells were
serum starved for 24 h before being stimulated with EGF at a final
concentration of 100 ng/ml for the time points specified before being fixed.
Reagents used in this study include: ProQ diamond stain (Thermo Fisher
Scientific), antibodies against FLAG M2 (Sigma, F3165; 1:1000), PAR6B
(Santa Cruz Biotechnology, sc, H-64, 1:500), FARP1 (Santa Cruz
Biotechnology, sc-74927, K-20, 1:250), FARP2 (Santa Cruz
Biotechnology, sc-390744, H-9, 1:250), aPKC (BD Biosciences C-20,
western blotting at 1:1000, immunofluorescence at 1:250) and GFP (FL,
1:1000) antibodies (Santa Cruz Biotechnology), phospho-PKA Substrate
(RRXS*/T*) (100G7E, 1:1000) and phospho-(Ser) PKC substrate antibody
(1:1000, Cell Signaling Technology), aPKC antibody (Cat number: 610608,
1:1000) (BD Transduction Laboratories), GAPDH antibody (MAB374,
Millipore; 1:5000), HRP-conjugated secondary antibody (GE Healthcare),
and ZO-1 (33-9100, Invitrogen, 1:400).
3D cultures were generated using CaCo2 cells. Briefly, cells were seeded
and reverse transfected with siRNA, left for 3 days then seeded in eight-well
chambers pre-coated with a 80% Matrigel and 20% collagen mix (Thermo
Fisher Scientific, BD and Amsbio). Cells were resuspended at 8000 cells/ml
in medium containing 2% Matrigel. Medium was replenished at day 6 and
cells were fixed at day 8 with 10% formalin and processed for
immunofluorescence as previously described (Elbediwy et al., 2012).
Oligonucleotides, plasmids and cloning
For siRNA-mediated knockdown, oligonucleotides were obtained from (GE
Dharmacon). The following siRNAs were used: siCTL 1, 5′-UAAGGCU-
AUGAAGAGAUAC-3′; siCTL 2, 5′-UAGCGACUAAACACAUCAA-3′;
siFARP2-01, 5′- GAACAUACCUCAAGGAUUU-3′; siFARP2-02, GAT-
TTGGCTTGAACCTAT-3′; aPKC#1, 5′-GGGUACAGACAGAGAAGC-
AUU-3′; aPKC#2, 5′- GUGUUUGAGCAGGCAUCCAUU-3′; Cdc42-
01, 5′-CGGAAUAUGUACCGACUGU-3′; and Cdc42-02, 5′-GAUG-
ACCCCUCUACUAUUG-3′. C-terminal FLAG–Myc-tagged FARP1
(RC208329) and FARP2 (RC216784) human cDNA constructs were
purchased from OriGene. Sequencing revealed that both plasmids contain
mutations different from the WT sequences. Therefore, site-directed
mutagenesis (Quikchange, Agilent) was employed to obtain WT sequences
(FARP1 Y644H FW, 5′-CTCACCTGTGGAAGCAGCGAGGCCTTG-3′;
FARP2 P375S FW, 5′-CAAGACCCACACGTCCGTTCGAGCTCTG-3′),
subsequently S340 or S370 mutations were introduced via Quikchange
(FARP2 S340 FW: 5′-CAGCCGGGGCTCCGCCTTCAGATACAGT-3′;
S370 FW: 5′-CGGACGTGTGGGTCTTGGCGTGCCTTCTTTCATATG-
3′). siRNA-resistant mutants of FARP2 were also obtained via Quikchange
(nt, 1644A>T, 1647A>T; FW 5′-GAGATTCTCGCTACAGAACGGAC-
TTACCTCAAGGATTTAGAAGT-3′). The FARP2 FERM-FA domain
was cloned in pCMV6-Entry (OriGene) using the following primers: Farp2-
FERMFA-Fw, 5′-GATATAGCGATCGCCATGGGGGAGATAGAA-3′;
and Farp2-FERMFA-Rv, 5′-CGATATACGCGTAGGAGTCCTCAATCC-
CTC-3′. aPKC constructs used in this paper have been described elsewhere
(Linch et al., 2013). To express the FARP2 FERM-FA and aPKCι kinase
domains in sf21 insect cells, the FERM-FA domain was cloned in
pBacPAK-His3 via in-fusion (Takara) using the following primers:
FW, 5′-ACCATCACGGGTCGACACAAGAGAAGCACCTGCAC-3′ and
RV, 5′-GGCCGCCCGGGAATTCCTAAGGAGTCCTCAATCCC-3′. The
pBacPAK-His3-GSTPKCι kinase domain construct was as previously
described (Kjaer et al., 2013).
Transfections, immunoprecipitation and protein purification
HCT116 cells were transiently transfected with cDNA using FuGENE HD
transfection reagent (Promega) according to the manufacturer’s instructions.
Caco2 cells were transiently transfected with cDNA using Lipofectamine
LTX with Plus reagent (Thermo Fisher Scientific) according to the
manufacturer’s instructions. For siRNA transfections, HCT116 cells were
reverse transfected with siRNA using HiPerFect siRNA transfection reagent
(Qiagen). siRNA was used at 20 nM unless otherwise stated. Caco2 cells
were reverse transfected with siRNA using Lipofectamine RNAiMAX
Fig. 4. Hypothetical model of a feedback activationmechanism for aPKC during junction establishment andmaintenance. FARP2 associates with aPKC
via a kinase domain RIPR-motif–FARP2FERM-FA interaction. Phosphorylation of FARP2 at S340 and S370 (red circles; dashed arrow) in the FA domain
results in dissociation of the complex and promotes localised function of FARP2 at the junctions (indicated by the curly bracket), where it activates Cdc42.
Activated Cdc42 (ovals with red to green transition; Ccd42 as a possible partner in membrane-associated aPKC–Par6 complexes is depicted in a faded shade)
can activate downstream effectors such as aPKC containing complexes. Maintained aPKC activity results in continuous FARP2 phosphorylation, resulting in a
positive-feedback cycle necessary to initiate and maintain junctions. FARP2 is also active independently of phosphorylation as depicted in the model.
PPtase, phosphatase mediating dephosphorylation of FARP2.
7
SHORT REPORT Journal of Cell Science (2019) 132, jcs223743. doi:10.1242/jcs.223743
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
(Thermo Fisher Scientific). siRNA was used at 40 nM unless stated
otherwise.
GFP-traps and FLAG immunoprecipitations were performed using GFP-
Trap-M magnetic beads (Chromotek) and FLAG-M2 beads (Sigma); FLAG
immunoprecipitations were performed using FLAG-M2 magnetic agarose
resin (Sigma), and uncoupled magnetic particles (Chromotek) were used for
pre-clearing. Co-immunoprecipitation was typically performed at 48 h after
cDNA transfection and 72 h after siRNA transfection. Cellswere lysed in lysis
buffer [20 mMTris-HCl pH 8, 130 mMNaCl, 1% (w/v) Triton X-100,1 mM
DTT, 10 mM NaF with added protease inhibitor cocktail (CoMplete, Roche)
and phosphatase inhibitor cocktail set II and set IV (Merck Millipore)]. Cell
lysates were centrifuged at 16,000 g in a table top centrifuge for 10 min at 4°C.
The supernatant was pre-cleared by incubation with magnetic particles
(Chromotek) at 4°C for 1 h while rotating. Pre-cleared lysates were incubated
with beads at 4°C for 90 min on a rotatingwheel. Beadswere thenwashed five
times with co-IP wash buffer followed by elution with 2× Laemmli sample
buffer. Co-immunoprecipitation samples were boiled at 95°C for 5 min and
analysed by SDS-PAGE and immunoblotting.
Co-expression of FARP2-FERM-FA and aPKCι kinase domain
followed by size-exclusion chromatography
Viruses encoding His–FARP2 FERM-FA and the GST–His-tagged PKCι
kinase domain were used to infect 50 ml cultures of Sf21 cells at 1×106
cells/ml [multiplicity of infection (MOI)=1]. Cultures were allowed to grow
for three days after which the cells were harvested and lysed. GST–His-
PKCι kinase domain – His–FARP2 FERM-FA complexes were purified
from Sf21 cultures using glutathione–Sepharose. Complexes were eluted
from the resin by 3C protease cleavage (Francis Crick Institute, Science
Technology Platform), and the eluates was loaded on an S200 increase
size exclusion column (GE Healthcare). Elution fractions were analysed
by SDS-PAGE.
Ca switch and TER
A junction formation assay based on a Ca2+ switch was performed as
previously described and processed for either immunofluorescence or TER
(Elbediwy et al., 2012). Cell maintenance TER measurements were
performed in normal medium. Briefly cells were reverse transfected, and
left for 24 h before being reseeded in transwells. TER was assessed at 48 h
post transfection and the protocol used was as previously described
(Elbediwy et al., 2012).
G-LISA
Cdc42 and Rac1/2/3 activity was assessed using a colorimetric based
G-LISA activation assay kit (Cytoskeleton). On day 1, Caco2 cells were
reverse transfected with 80 nM of siRNA. On day 4 (72 h post transfection),
cells were washed on ice with cold PBS and processed according to the
manufacturer’s instructions (Elbediwy et al., 2012).
FRET-FLIM
FLIM microscopy was performed using a Leica SP8 confocal microscope.
GFP–PKCι was excited with a 488 nm pulsed laser excitation and, for
samples co-transfected with FARP2–FLAG and labelled with an anti-HA
antibody conjugated to Alexa Fluor 647 (Cell Signaling), a 640 nm laser was
used to collect a standard confocal image. Using FLIMfit (Warren et al.,
2013) to analyse the lifetime decays, data from28 different cells contributed to
the donor-only histogram and 80 cells contributed to the donor-plus-acceptor
histogram. Regions of interest corresponding to cell membranes were drawn
by hand and the values of the calculated lifetimes for these pixels were
combined into intensity weighted histograms of donor-only or donor-plus-
acceptor lifetimes. These distributions were converted into distributions of
FRET efficiency.
Quantification
Quantification of continuous staining for ZO-1, aPKC or transfected FARP
WT in Caco-2 cells was scored as either a continuous stain, in which the
junctional antibody staining formed a complete ring around the cell, or
discontinuous, in which the junctional antibody staining was repeatedly
broken or fragmented around the cell. Cells were assessed over three
independent experiments counting 50–200 transfected cells for each
condition or 200–500 non-transfected cells. This method was described
previously (Aguilar-Aragon et al., 2018; Elbediwy et al., 2012). For graph
production and statistical significance, Prism was used and the software
automatically calculated the statistical significance using a Student’s t-test.
Error bars represent the s.d. Significance as illustrated by the presence of
asterisks is as follows: ns, not significant (P>0.05); *P≤0.05; **P≤0.01;
***P≤0.001; ****P≤0.0001.
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